Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.03 EUR
13.50 B EUR
38.82 B EUR
3.15 B
About NOVO NORDISK B A/S
Sector
CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Website
Founded
1931
ISIN
DK0062498333
FIGI
BBG00KDZJQ50
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
No news here
Looks like there's nothing to report right now
Finally a stock I like...this one is a real dealFinally, an investment idea! (after how much doom and gloom?) — Novo Nordisk.
You will all be familiar with Ozempic, the Danish company’s flagship product and the reason so many celebrities, influencers, b listers and regular schmegular Americans are suddenly skinny. I ignored the stock for most of
I am cautiously calling the bottom on NVOIt might be a bit early to call this a bottom, especially given the unpredictable market, but I’m noticing a few key signals aligning:
The 8/21 curl following a double bottom
A break above the 50-day SMA occurring on a red day like today
Momentum shifting positive and being released from a squ
Opening (IRA): NVO March 28th 76 Covered Call... for a 74.50 debit.
Comments: Taking what amounts to a modest directional shot with a break even below the 52-week lows, selling the -75 delta call against shares to emulate the delta metrics of a 25 delta short put, but with the built-in defense of the short call.
Metrics:
Buying Power Effec
Buy Opportunity for NVONovo Nordisk A/S – Financial Summary and Outlook (2024):
Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER).
Operating Profit: Increased by 21% (DKK 91.6 billion).
Net Profit: Rose 18% to DKK 72.8 billion.
Product Highlights:
Wegovy (Obesity)
$NVO more pain ahead! Headed down to $46-55 - NYSE:NVO was one of the hottest stocks of 2024 is now facing immense challenges by other healthcare companies in weight loss drug.
- With weak results, it sets up for disappointment for 1-2 quarters. Quick turnaround in experiments isn't feasible and would need considerable time to show promis
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
XS234803042
NOVO NO.F.NL 21/28Yield to maturity
2.68%
Maturity date
Jun 4, 2028
XS244933017
NOVO NO.F.NL 22/27MTNYield to maturity
2.52%
Maturity date
Sep 30, 2027
XS244124453
NOVO NO.F.NL 22/25 MTNYield to maturity
2.12%
Maturity date
Mar 31, 2025
Explore more bonds
Curated watchlists where NNO2 is featured.
Frequently Asked Questions
The current price of NNO2 is 85.48 EUR — it has increased by 1.33% in the past 24 hours. Watch NOVO-NORDISK AS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange NOVO-NORDISK AS stocks are traded under the ticker NNO2.
NNO2 stock has risen by 11.06% compared to the previous week, the month change is a 9.42% rise, over the last year NOVO-NORDISK AS has showed a −25.33% decrease.
We've gathered analysts' opinions on NOVO-NORDISK AS future price: according to them, NNO2 price has a max estimate of 154.11 EUR and a min estimate of 69.01 EUR. Watch NNO2 chart and read a more detailed NOVO-NORDISK AS stock forecast: see what analysts think of NOVO-NORDISK AS and suggest that you do with its stocks.
NNO2 reached its all-time high on Jun 25, 2024 with the price of 137.98 EUR, and its all-time low was 17.95 EUR and was reached on Oct 11, 2018. View more price dynamics on NNO2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NNO2 stock is 1.98% volatile and has beta coefficient of 1.48. Track NOVO-NORDISK AS stock price on the chart and check out the list of the most volatile stocks — is NOVO-NORDISK AS there?
Today NOVO-NORDISK AS has the market capitalization of 374.95 B, it has decreased by −3.48% over the last week.
Yes, you can track NOVO-NORDISK AS financials in yearly and quarterly reports right on TradingView.
NOVO-NORDISK AS is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NNO2 earnings for the last quarter are 0.85 EUR per share, whereas the estimation was 0.80 EUR resulting in a 6.08% surprise. The estimated earnings for the next quarter are 0.85 EUR per share. See more details about NOVO-NORDISK AS earnings.
NOVO-NORDISK AS revenue for the last quarter amounts to 11.46 B EUR, despite the estimated figure of 10.71 B EUR. In the next quarter, revenue is expected to reach 10.99 B EUR.
NNO2 net income for the last quarter is 3.77 B EUR, while the quarter before that showed 3.66 B EUR of net income which accounts for 3.14% change. Track more NOVO-NORDISK AS financial stats to get the full picture.
NOVO-NORDISK AS dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Feb 25, 2025, the company has 76.30 K employees. See our rating of the largest employees — is NOVO-NORDISK AS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO-NORDISK AS EBITDA is 19.99 B EUR, and current EBITDA margin is 50.95%. See more stats in NOVO-NORDISK AS financial statements.
Like other stocks, NNO2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO-NORDISK AS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO-NORDISK AS technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO-NORDISK AS stock shows the neutral signal. See more of NOVO-NORDISK AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.